trial

Evaluate the Pharmacokinetics of Quetiapine Fumarate in Chinese Schizophrenic Patients

NCTId NCT00919607
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 1 · Completed
Enrollment 31 (actual)
Sponsored by AstraZeneca
Primary completion 2010-03
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 1
Status
Completed
Enrollment
31 (actual)
Study type
Interventional
Allocation
Randomized
Model
Single Group
Masking
None
Start
2009-06
Primary completion
2010-03
Eligibility
ALL · 18 Years · 60 Years

Interventions & indications

Drugs
Quetiapine

Sponsors

AstraZenecaLead Sponsor

Investigators

1
Tianmei Si, MDPrincipal Investigator

Sites

1 total
Beijing, China

Facts & assertions

4 sourced
Enrollment
31
Phase
PHASE1
Primary Completion Date
2010-03
Status
COMPLETED
relationships
The graph out of here
drug
Quetiapine
drug
lead_sponsor
AstraZeneca
company
indication
Schizophrenia
indication
Schizophrenia
indication
investigator
Tianmei Si, MD
person